Innohep (Tinzaparin Sodium)

Innohep, a low molecular weight heparin, is used in clinical situations where inhibition of clot formation is required.

• Deep vein thrombosis (prevention): Reduces the incidence of clot formation in at‑risk patients.
• Deep vein thrombosis (treatment): Promotes resolution of existing thrombi and prevents extension.
• Pulmonary embolism (prevention): Lowers the risk of embolic events after major surgery or immobilisation.
• Surgical anticoagulation: Provides peri‑operative anticoagulation to minimise postoperative thrombotic complications.

• Tinzaparin sodium binds to antithrombin III, markedly accelerating its inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This reduces thrombin generation and fibrin clot formation, thereby providing anticoagulant protection in the venous circulation.

Common Side Effects

• Injection site erythema or bruising: Local irritation at the subcutaneous site.
• Minor bleeding: Nosebleeds, gum bleeding, or easy bruising.
• Headache: Mild to moderate discomfort.
• Nausea: Transient gastrointestinal upset.
• Elevated liver enzymes: Mild, reversible changes in hepatic labs.

Serious or Rare Side Effects

• Major hemorrhage: Life‑threatening bleeding requiring medical intervention.
• Heparin‑induced thrombocytopenia (HIT): Immune‑mediated platelet decline with paradoxical clot risk.
• Spinal or epidural hematoma: Bleeding in the central nervous system after neuraxial procedures.
• Severe allergic reaction: Anaphylaxis or systemic urticaria.
• Acute adrenal hemorrhage: Rare but potentially fatal adrenal bleeding.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely.

• Renal function assessment: Adjust dosing in patients with impaired clearance.
• Platelet count monitoring: Detect early signs of HIT.
• Bleeding risk evaluation: Review history of recent surgery or trauma.
• Concomitant anticoagulant use: Avoid or adjust doses of other blood thinners.
• Elderly patients: Use caution due to increased sensitivity.
• Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): Heightened bleeding risk.
• Antiplatelet agents (e.g., aspirin, clopidogrel): Additive antithrombotic effect.
• Fibrinolytic therapy (e.g., alteplase): Potentiates hemorrhage.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Increases mucosal bleeding.
• Neuraxial anesthesia or spinal puncture: Risk of spinal hematoma.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: May enhance hypotensive effects.
• Diuretics: Potential for volume depletion and renal impact.
• Certain antibiotics (e.g., vancomycin): May alter platelet function.
• Hormonal contraceptives: Slight increase in thrombotic tendency.
• Lipid‑lowering agents (e.g., statins): Monitor liver enzymes.